[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585025":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":60,"collaborators":63,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":42,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":42,"enrollmentInfo":81,"targetDuration":42,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":46,"whyStopped":42,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"the esketamine group","EXPERIMENTAL","In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine. A total of 0.5 mg\u002Fkg of esketamine will be diluted in 50 mL of normal saline. The infusion will commence with an intravenous injection of 10 mg of esketamine over 1 minute, followed by a maintenance dose of 8 mg\u002Fh. The infusion rate will be adjusted based on the patients' tolerance levels.",[13],"Drug: esketamine group",{"label":15,"type":16,"description":17,"interventionNames":18},"the control group","PLACEBO_COMPARATOR","In the control group, patients will receive pregabaline combined with duloxetine. Pregabaline will be administered at a dose of 50-75 mg, twice daily during the first 3 days of treatment, and increase to 300mg daily after 3-7days, then by an additional 150mg daily every 3-7 days as tolerated, up to a maximum daily dose of 600mg. Meanwhile, duloxetine will be prescribed at an initial daily dose of 30mg, and then gradually increased to 60 mg daily after one week if patients tolerate it well.",[19],"Drug: control group",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","esketamine group","In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.",[9],[27],"pregabalin+duloxetine+esketamine",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"control group","receiving the combination of pregabalin and duloxetine",[15],[33],"pregabalin+duloxetine",[35],{"name":36,"affiliation":5,"role":37},"Fang Luo, M.D.","PRINCIPAL_INVESTIGATOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+86 13611326978",null,"13611326978@163.com",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Beijing","Beijing Municipality","100070","China","CN",{"type":53,"coordinates":54},"Point",[55,56],116.39723,39.9075,{"lat":56,"lon":55},[59],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},{"type":37,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Fang Luo","The Director of Department of Pain Management",[64,66,68,70],{"name":65,"class":6},"Beijing Xiaotangshan Hospital",{"name":67,"class":6},"The First Hospital of Fangshan District,Beijing",{"name":69,"class":6},"Beijing Ditan Hospital",{"name":71,"class":6},"Hengshui People's Hospital","100585025","esketamine-combined-pregabalin-and-duloxetine-for-postherpetic-neuralgia-100585025",false,"NCT06896994","Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia","Intravenous Infusion of Esketamine in Combination With Pregabalin and Duloxetine for Postherpetic Neuralgia","Inclusion Criteria:\n\n1. Ages more than 18 years;\n2. Pain present for more than 3 months after healing of a herpes zoster skin rash;\n3. Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)；\n4. Failed to respond to or tolerate the effective dose of pregabalin monotherapy.\n\nExclusion Criteria:\n\n1. Obstructive sleep apnoea syndrome;\n2. Those who receive interventional treatments;\n3. A history of systemic immune diseases, organ transplantation, or cancers;\n4. A history of severe cardiopulmonary, hepatic or renal dysfunction;\n5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;\n6. Currently using monoamine oxidase inhibitors (MAOIs);\n7. Having untreated angle-closure glaucoma;\n8. Those suffering from increased intracranial pressure；\n9. Comorbid hyperthyroidism or phaeochromocytoma;\n10. Suspected or confirmed history of drug abuse;\n11. Having contraindications to esketamine, pregabaline or duloxetine;\n12. Communication difficulties;\n13. Women who are preparing for pregnancy, in the pregnancy or lactation period.","ALL","18 Years",{"count":82,"type":83},150,"ESTIMATED","INTERVENTIONAL",[86],"NA","To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).",[89],"Postherpetic Neuralgia",[89,91],"esketamine","2025-04-24",{"date":94,"type":95},"2025-04-27","ACTUAL",{"date":97,"type":95},"2025-04-01",{"date":99,"type":83},"2026-05-01",{"name":5,"class":6},1]